- Home
- FENC
as 07-26-2024 4:00pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 181.7M | IPO Year: | 2001 |
| Target Price: | $16.00 | AVG Volume (30 days): | 107.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.66 - $11.92 | Next Earning Date: | 08-05-2024 |
| Revenue: | $44,952,000 | Revenue Growth: | 1299.50% |
| Revenue Growth (this year): | 202.07% | Revenue Growth (next year): | 6.78% |
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RALLIS CHRIS A | FENC | Director | Jul 5 '24 | Sell | $6.03 | 1,173 | $7,073.19 | 46,457 | SEC Form 4 |
| Raykov Rosty | FENC | CHIEF EXECUTIVE OFFICER | Jul 1 '24 | Sell | $6.13 | 2,431 | $14,902.03 | 187,471 | SEC Form 4 |
| Raykov Rosty | FENC | CHIEF EXECUTIVE OFFICER | Jun 3 '24 | Sell | $6.76 | 2,431 | $16,433.56 | 187,471 | SEC Form 4 |
| Raykov Rosty | FENC | CHIEF EXECUTIVE OFFICER | Apr 30 '24 | Sell | $9.11 | 2,431 | $22,152.00 | 187,471 | SEC Form 4 |
| Haigh Adrian | FENC | CHIEF OPERATING OFFICER | Apr 19 '24 | Sell | $9.34 | 22,222 | $207,442.37 | 0 | SEC Form 4 |
| Haigh Adrian | FENC | CHIEF OPERATING OFFICER | Apr 19 '24 | Sell | $9.32 | 22,223 | $207,029.47 | 0 | SEC Form 4 |
| Haigh Adrian | FENC | CHIEF OPERATING OFFICER | Apr 17 '24 | Sell | $2.31 | 22,222 | $51,332.82 | 22,222 | SEC Form 4 |
| Haigh Adrian | FENC | CHIEF OPERATING OFFICER | Apr 17 '24 | Sell | $2.31 | 22,222 | $51,332.82 | 44,444 | SEC Form 4 |
| Haigh Adrian | FENC | CHIEF OPERATING OFFICER | Apr 17 '24 | Sell | $9.91 | 22,222 | $220,220.02 | 22,222 | SEC Form 4 |
| Haigh Adrian | FENC | CHIEF OPERATING OFFICER | Apr 17 '24 | Sell | $9.62 | 22,222 | $213,775.64 | 0 | SEC Form 4 |
| Haigh Adrian | FENC | CHIEF OPERATING OFFICER | Apr 15 '24 | Sell | $2.31 | 22,222 | $51,332.82 | 22,222 | SEC Form 4 |
| Haigh Adrian | FENC | CHIEF OPERATING OFFICER | Apr 15 '24 | Sell | $2.31 | 22,222 | $51,332.82 | 44,444 | SEC Form 4 |
| Haigh Adrian | FENC | CHIEF OPERATING OFFICER | Apr 15 '24 | Sell | $10.30 | 22,222 | $228,793.27 | 22,222 | SEC Form 4 |
| Haigh Adrian | FENC | CHIEF OPERATING OFFICER | Apr 15 '24 | Sell | $10.28 | 22,222 | $228,388.83 | 0 | SEC Form 4 |
| RALLIS CHRIS A | FENC | Director | Apr 15 '24 | Sell | $10.45 | 800 | $8,360.00 | 44,449 | SEC Form 4 |
| Raykov Rosty | FENC | CHIEF EXECUTIVE OFFICER | Apr 4 '24 | Sell | $10.89 | 14,583 | $158,871.58 | 261,471 | SEC Form 4 |
| Raykov Rosty | FENC | CHIEF EXECUTIVE OFFICER | Apr 4 '24 | Sell | $10.89 | 29,700 | $323,528.04 | 231,771 | SEC Form 4 |
| Raykov Rosty | FENC | CHIEF EXECUTIVE OFFICER | Apr 4 '24 | Sell | $10.75 | 44,300 | $476,269.30 | 187,471 | SEC Form 4 |
| Raykov Rosty | FENC | CHIEF EXECUTIVE OFFICER | Apr 3 '24 | Sell | $10.78 | 14,584 | $157,189.27 | 302,054 | SEC Form 4 |
| Raykov Rosty | FENC | CHIEF EXECUTIVE OFFICER | Apr 3 '24 | Sell | $10.78 | 26,000 | $280,261.80 | 276,054 | SEC Form 4 |
| Raykov Rosty | FENC | CHIEF EXECUTIVE OFFICER | Apr 1 '24 | Buy | $0.00 | 29,167 | $0.00 | 316,638 | SEC Form 4 |
| Andrade Robert | FENC | CHIEF FINANCIAL OFFICER | Apr 1 '24 | Buy | $0.00 | 12,500 | $0.00 | 104,271 | SEC Form 4 |
| Andrade Robert | FENC | CHIEF FINANCIAL OFFICER | Mar 26 '24 | Sell | $10.90 | 13,975 | $152,345.67 | 91,771 | SEC Form 4 |
| RALLIS CHRIS A | FENC | Director | Mar 26 '24 | Sell | $10.97 | 2,114 | $23,190.58 | 40,920 | SEC Form 4 |
| Andrade Robert | FENC | CHIEF FINANCIAL OFFICER | Jan 4 '24 | Sell | $10.64 | 15,000 | $159,600.00 | 134,721 | SEC Form 4 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
Zacks
12 days ago
Implied Volatility Surging for Fennec (FENC) Stock Options
MT Newswires
25 days ago
MT Newswires Weekend Stocks To Watch: BCE; Bitfarms; Fennec; GreenPower; Hut 8; Restaurant Brands; Sigma Lithium; Solaris
MT Newswires
a month ago
Fennec Pharmaceuticals Chief Operating Officer Adrian Haigh Steps Down
GlobeNewswire
a month ago
Fennec Pharmaceuticals Announces Management Change
GlobeNewswire
a month ago
Fennec Announces Results of Annual Meeting
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Compare FENC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.